ArticleJournal of gastrointestinal oncology2025
The molecular sub-type and the development and validation of a prognosis prediction model based on endocytosis-related genes for hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of VPS45 in HCC and Its Correlation with Immune Microenvironment.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the critical role of endocytosis-related genes in oncogenic processes, research exploring their potential for prognosticating hepatocellular carcinoma (HCC) remains limited. Establishing a connection between endocytosis and HCC is imperative. This study aimed to create a gene signature related to endocytosis to identify HCC subtypes and predict outcomes. Methods: RNA sequencing and clinical data of 371 HCC patients were obtained from The Cancer Genome Atlas (TCGA)-HCC dataset. Subtypes of HCC were identified through endocytosis-associated genes through consistent clustering analysis, and prognosis was assessed using an endocytosis-associated HCC model. Construction and validation of a prognostic endocytosis-related risk scoring system were created for HCC. Results: A univariate Cox regression analysis was performed using the TCGA-HCC dataset, resulting in the identification of 4,354 genes significantly associated with patient prognosis. Subsequent Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of these genes identified several biologically relevant pathways, particularly those related to endocytosis, autophagy, and cell cycle regulation. Through the application of consensus clustering methods, patients with TCGA-HCC were stratified into two distinct subtypes based on a selection of 82 genes associated with endocytosis. Importantly, the overall survival rate for the high-risk subtype (C1) was significantly higher than that of the low-risk subtype (C2). KEGG analysis indicated that the upregulated genes in the high-risk C1 subtype were predominantly related to various pathways, including the p53 signaling pathway, proteoglycans in cancer, cell cycle regulation, interactions between the extracellular matrix and receptors, and cellular senescence. In contrast, in the comparison between the C1 and C2 HCC samples, the genes exhibiting downregulation were predominantly linked to metabolic pathways, including tyrosine metabolism and steroid hormone biosynthesis. Boxplots showed significant differences in immune cell populations, including CD4 Conclusions: Genes linked to endocytosis strongly correlate with tumor classification in patients with HCC. The related expression profiles may be valuable for predicting HCC prognosis and informing diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.